Teva Pharmaceutical Industries Limited (TEVA) – Can TEVA save Copaxone?

in , , on September 6, 2022

This report is useful for M&A and business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for insights on any specific sector/industry and market recommendations.

Teva Pharmaceutical Industries Limited (TEVA)

TEVA’s performance can be attributed to the sale of its patent drugs. The management of the company has
adopted a strategic initiative where the focus of the company have shifted to patent drugs.



– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– PE Chart and Comparisons
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance


Stock Price Performance

Crispidea Coverage

No of Pages : 29

Release Information

  • Price


  • Released

    September 6, 2022

  • Last Updated

    September 9, 2022